

UNITED STATES DEPARTMENT OF COMMERCE

Patent and Trademark Offic

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO.

09/398,610

LCUIS MYERS

FISH & RICHARDSON PC

225 FRANKLIN STREET BOSTON MA 02110-2804

09/17/99

EDGE

[7]

10275/137001

HM22/1215

EXAMINER

KERR, J

ART UNIT

PAPER NUMBER

1633

DATE MAILED:

12/19/00

Please find below and/or attached an Office communication concerning this application or pr ceeding.

Commissioner of Patents and Trademarks

Office Action Summary

فارست يجسمه

**

Application No. 09/398,610

Applicant(s)

_

Edge et al.

Examiner

Janet M. Kerr

Group Art Unit 1633



X Responsive to communication(s) filed on Sep 17, 2000	
☐ This action is FINAL .	
☐ Since this application is in condition for allowance except for f	formal matters, prosecution as to the merits is closed
in accordance with the practice under Ex parte Quayle, 1935	
A shortened statutory period for response to this action is set to easy longer, from the mailing date of this communication. Failure to application to become abandoned. (35 U.S.C. § 133). Extension 37 CFR 1.136(a).	respond within the period for response will cause the
Disposition of Claims	
	is/are pending in the application.
Of the above, claim(s)	is/are withdrawn from consideration.
Claim(s)	is/are allowed.
☐ Claim(s)	
☐ Claim(s)	
Application Papers	
 See the attached Notice of Draftsperson's Patent Drawing F 	Review, PTO-948.
☐ The drawing(s) filed on is/are objected	
☐ The proposed drawing correction, filed on	
☐ The specification is objected to by the Examiner.	
☐ The oath or declaration is objected to by the Examiner.	
Priority under 35 U.S.C. § 119	
Acknowledgement is made of a claim for foreign priority un	nder 35 U.S.C. § 119(a)-(d).
☐ All ☐ Some* ☐ None of the CERTIFIED copies of the	
☐ received.	
☐ received in Application No. (Series Code/Serial Numb	per)
\square received in this national stage application from the In	iternational Bureau (PCT Rule 17.2(a)).
*Certified copies not received:	
☐ Acknowledgement is made of a claim for domestic priority	under 35 U.S.C. § 119(e).
attachment(s)	
☐ Notice of References Cited, PTO-892	
☐ Information Disclosure Statement(s), PTO-1449, Paper No(s	s)
☐ Interview Summary, PTO-413	
☐ Notice of Draftsperson's Patent Drawing Review, PTO-948	
☐ Notice of Informal Patent Application, PTO-152	
SEE OFFICE ACTION ON THE	F FOLLOWING PAGES

Application/Control Number: 09/398,610

Art Unit: 1633

Signamani 1 & 7

Election/Restriction

This application contains claims directed to the following patentably distinct species of the claimed invention: fusion proteins including an immunoglobulin-subunit and enzyme, a subunit of a targeting molecule and a cell toxin, a subunit of an Ig specific for any one of tumor antigens carcinoembryonic antigen, transferrin receptor, TAG-72, and epidermal growth factor receptor, a fusion protein including an RNASE, a fusion protein including angiogenin, a fusion protein including carboxypeptidase B enzyme. The species are distinct as the fusion proteins are structurally and functionally distinct, each from the other.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, the method of making a transgenic fusion protein comprising providing a transgenic animal which includes a transgene which provides for the expression of the fusion protein, allowing the transgene to be expressed, and recovering the fusion protein from the milk of the animal, is generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janet M. Kerr whose telephone number is (703) 305-4055. Should the examiner be unavailable, inquiries should be directed to Deborah Clark, Supervisory Primary Examiner of Art Unit 1633, at (703) 305-4051. Any administrative or procedural questions should be directed to Kimberly Davis, Patent Analyst, at (703) 305-3015. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center number is (703) 305-7401.

The Group and/or Art Unit location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1633.

Janet M. Kerr, Ph.D.

Patent Examiner

Group 1600

KAREN M. HAUDA

SUPERVISORY PATENT EXAMINER

Kaun M. Handa

TECHNOLOGY CENTER 1600